The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) is a European collaboration to improve the knowledge, diagnosis and treatment of Alzheimer's by using a Positron Emission Tomography (PET).
AMYPAD is made up of 17 European institutions, including research centers, pharmaceuticals and patient associations.
The project consists of three studies:
- Diagnostic study: it will focus on determining the amyloid PET value in the diagnosis and clinical management of people in a spectrum ranging from subjective complaints of memory, to mild cognitive impairment and dementia.
- Prognosis study: will be carried out to better understand the natural history of the disease, in coordination with the EPAD longitudinal cohort study (European Prevention of Alzheimer's Dementia).
- Concept test study: models of evolution of the disease will be constructed, the definition of inclusion criteria in clinical trials will be made, and will allow monitoring the effectiveness of the new treatments in an individualized way.
The project will involve 3,100 people from all over Europe and 6,000 amyloid PET will be made. Barcelonaβeta Brain Research Center participates in the design of the project, in the different working groups and in the recruitment of participants.
AMYPAD has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Principal Investigator of AMYPAD at BBRC
José Luis Molinuevo, scientific director of the Alzheimer's Prevention Program.
Molinuevo is co-author of more than 280 scientific articles with more than 10,000 citations in prestigious journals, and a 53 h index. In addition, he participates in networks related to the standardization of procedures and clinical criteria of Alzheimer’s disease, such as the Alzheimer Biomarker Standarization Initiative, the International Working Group, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research framework, the CSF Appropriate Use Criteria Workgroup, the Standardization of CSF Preanalytics Working Group and the Subjective Cognitive Decline Initiative (SCD-I) Working Group.